The MCRN Approach
Bringing More Clinical Trials, to More Patients, in More Centres Across Canada
The MCRN brings innovative Canadian-designed clinical trials to hundreds of patients in provinces across Canada, in order to study the efficacy of new treatments that are not yet approved by Health Canada or new treatment combinations. Furthermore, focusing on high-impact Phase I and Phase II clinical trials, the collaboration amongst the centres allows the network of researchers to leverage expertise and share findings and knowledge amongst all of the members across the country, specifically in:
- Drug target evaluation
- Minimal residual disease • Mechanisms of resistance • Cell therapy
- High-risk disease
As the MCRN's clinical trial portfolio continues to grow, and with the recent launch of the MCRN Canadian Multiple Myeloma Database, we will now be able to better gather patient outcome data from across the country to identify the optimal treatment approaches, using real-world evidence. The national database will also help support public funding decisions with real-world data that will provide compelling clinical evidence to confirm the superiority of a novel treatment or combination.
Ultimately, research conducted in this collaborative, entrepreneurial setting promotes the advancement of clinical research and dissemination of results at an accelerated pace in Canada.